Used primarily in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulation of dopamine signaling. Its ability to modulate intracellular cAMP and cGMP levels in the brain makes it a valuable tool for studying striatal pathways associated with cognition, motivation, and motor control. Due to its high blood-brain barrier permeability and favorable pharmacokinetic profile in preclinical models, it serves as a lead compound in the development of novel antipsychotic agents with improved efficacy and fewer side effects compared to current treatments.